mFOLFIRI plus | mFOLFIRI plus | |
---|---|---|
Bevacizumab (n=42) | Panitumumab (n=44) | |
Analyzed | n=31 | n=44 |
Mean age (range), years | 75 (70-84) | 76 (70-88) |
ECOG PS 0/1/2 | 39/58/3 | 25/71/4 |
Male/Female | 81/19 | 73/27 |
Rectal Cancer | 16 | 25 |
Primary tumor not resected | 26 | 16 |
Overall Response Rate (95% CI), % | 41.9 (24.6%-59.3%) | 47.7 (32.9%-62.5%) |
Stable Disease, % | 38,7 | 15.9 |
PFS (95% CI), months | 8.6 (7.6-9.6) | 6.1 (3.6-8.7) |
OS (95% CI), months | 28.8 (16.5-41.1) | 20.9 (11.7-30.1) |
1-year survival, % | 77.4 | 68.2 |
Median Follow up, months | 39.5 | 36.0 |
Neutropenia | 19.3 | 9.0 |
Diarrhoea | - | 20.4 |
Mucositis | - | 2.3 |
Skin toxicity | - | 4.5 |
Fatigue | - | 4.5 |
Bowel perforation | - | 2.3 |
Paronychia | - | 2.3 |
Constipation | 3.2 | - |
Hypertension | 3.2 | - |
All | Frail G8 ≤14 | Fit G8>14 | |
---|---|---|---|
N=40 | N=29 | N=11 | |
Mean ±SD | 76 ± 4.3 | 73 ± 3 | 77 ± 4.3 |
Men | 25 | 17 | 8 |
Women | 15 | 12 | 3 |
0-1 | 27 | 17 | 10 |
2-4 | 13 | 12 | 1 |
Adjuvant | 7 | 4 | 3 |
Metastatic | 33 | 25 | 8 |
No | 18 | 11 | 7 |
Yes | 21 | 18 | 3 |
No | 26 | 15 | 11 |
Yes | 14 | 14 | 0 |